Skip to Main Content

Paper Details

Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy.
Oncotarget
20
2017
GLI1, GLI1 mRNA, Hedgehog, LDE-225, Sonidegib, hedgehog, localized prostate cancer, men, patient, patients, plasma, prostate cancer, prostate tumor, tumor
Author NameAffiliation
Ashley E RossJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine
Ashley E RossSidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Ashley E RossJohns Hopkins School of Medicine
Jeffrey J TosoianJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine
Luigi MarchionniJohns Hopkins School of Medicine
Luigi MarchionniSidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Luigi MarchionniJohns Hopkins School of Medicine
Luigi MarchionniSidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Edward M SchaefferJohns Hopkins School of Medicine
Edward M SchaefferJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine
Edward M SchaefferSidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Alan W PartinJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine
Alan W PartinJohns Hopkins School of Medicine
Alan W PartinSidney Kimmel Cancer Center, Johns Hopkins School of Medicine
Emmanuel S AntonarakisJames Buchanan Brady Urological Institute, Johns Hopkins School of Medicine
Emmanuel S AntonarakisJohns Hopkins School of Medicine
Emmanuel S AntonarakisSidney Kimmel Cancer Center, Johns Hopkins School of Medicine
  • 1 - 17

Datasets

Release 1.2